Glimepiride/Dapagliflozin Propanediol Monohydrate

格列美脲/达格列净丙二醇一水化物

Report date: 2026/02/06 20:01:23

Base Information

Drug NameGlimepiride/Dapagliflozin Propanediol Monohydrate
Drug Alias NameDAPAGREEN-G
ClassificationSmall molecules
Mechanisms of ActionKATP channels blockersSulfonylurea receptor modulatorsSodium/glucose cotransporter 2 inhibitors
TargetsSulfonylurea receptorKATP channelsSodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2023/02/22
Country/TerritorySouth Korea
CombinationsYes GlimepirideDapagliflozin Propanediol Monohydrate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesJinyang Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJinyang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A